Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keverprazan + amoxicillin dual therapy vs bismuth quadruple therapy for first-line Helicobacter pylori eradication
ChiCTR2600122928Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Apr 2026
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of keverprazan, amoxicillin, esomeprazole, bismuth subcitrate and clarithromycin in Helicobacter pylori infection (3 arms), sponsored by First Affiliated Hospital of Xiamen University. Primary endpoints: Eradication rate of Helicobacter pylori and Adverse events. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
keverprazanamoxicillinesomeprazolebismuth subcitrateclarithromycin
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2600122928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122928.